Biological understanding of the cardiovascular risk associated with major depression and panic disorder is important

International Journal of Psychiatry in Clinical Practice

Volumn 16, Issue 1, 2012, Pages 27-32

  Yapislar, Hande ^a,c   Aydogan, Sami ^a   Ozüm, Ünal ^b  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b CUMHURIYET UNIVERSITY   (Turkey)

^c ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

Homocysteine; Major depressive disorder; Nitric oxide; Panic disorder; Platelet aggregation

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HOMOCYSTEINE; NITRIC OXIDE;

ADULT; ANXIETY; ARTICLE; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR DEPRESSION; MALE; MENTAL DISEASE; PANIC; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STRESS; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; THROMBOCYTE AGGREGATION;

ADULT; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSIVE DISORDER, MAJOR; ENDOTHELIUM, VASCULAR; FEMALE; HOMOCYSTEINE; HUMANS; MALE; NITRIC OXIDE; NITRITES; PANIC DISORDER; PLATELET AGGREGATION; RISK FACTORS; SPECTROPHOTOMETRY;

EID: 84856851373     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2011.620127     Document Type: Article

References (45)

1. Craske MG, Kircanski K, Epstein A, Wittchen H.U, Pine DS, Lewis-Fernández R, Hinton D. DSM V anxiety; OC Spectrum; Posttraumatic and Dissociative Disorder Work Group. Panic disorder: a review of DSM-IV panic disorder and proposals for DSM-V. Depress. Anxiety 2010;27:93-112.
2. Muñoz RF, Cuijpers P, Smit F, Barrera AZ, Leykin Y. Prevention of major depression. Annu Rev Clin Psychol 2010; 27:181-212.
3. Nakashima MN, Ajiki K, Nakashima K, Takahashi M. Possible role of nitric oxide in anxiety following transient cerebral ischemia in mice. J Pharmacol Sci 2003;91:47-52. (Pubitemid 36575554)
4. Markovitz JH, Shuster JL, Chitwood WS, May RS, Tolbert LC. Platelet activation in depression and effects of sertraline treatment: An open-label study. Am J Psychiatry 2000;157:1006-8. (Pubitemid 30412355)
5. Ziegelstein RC, Parakh K, Sakhuja A, Bhat U. Depression and coronary artery disease: is there a platelet link? Mayo Clin Proc 2007;82:1366-8. (Pubitemid 350060133)
6. Tiemeier H. Vitamin B12, folate and homocysteine in depression. The Rotterdam Study. Am J Psychiatry 2002;159:2099-101. (Pubitemid 35423873)
7. Zhou L, Zhu DY. Neuronal nitric oxide synhase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 2009;20:223-30.
8. Joca SR, Guimaraes FS. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology 2006;185:298-305.
9. Herken H, Uz E, Ozyurt H, et al. Red blood cell nitric oxide levels in patient with schizophrenia. Schizophr Res 2001; 52:289-90. (Pubitemid 33052518)
10. Miguel TT, Nunes-de-Souza RL. Anxiogenic like effects induced by NMDA receptor activation are prevented by inhibition or neuronal nitric oxide synthase in the periaqueduc-tal gray in mice. Brain Res 2008;13:39-46.
11. Workman JL, Trainor BC, Finy MS, et al. Inhibition of neuronal nitric oxide reduces anxiety-like responses to pair housing. Behav Brain Res 2008;187:109-15. (Pubitemid 350216195)
12. Bottiglieri T, Laundy M, Crellin R, et al. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000;69:228-32. (Pubitemid 30466029)
13. Miller AL. The methylation, neurotransmitter, and antioxi-dant connections between folate and depression. Alternative Med Rev 2008;13:216-26.
14. Viinikka L. Nitric oxide as a challenge for the clinical chemistry laboratory. Scand J Clin Lab Invest 1996;56:577-81. (Pubitemid 26423582)
15. Tsikas D. Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the L-arginine/nitric oxide area of research. J Chromatogr B Anal Technol Biomed Life Sci 2007;851: 51-70. (Pubitemid 46720134)
16. Born G V. Light on platelets. J Physiol 2005;1:713-14. (Pubitemid 41646016)
17. Harkin A, Connor TJ, Walsh M, St John N, Kelly JP. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 2000; 44:616-23.
18. Joca SR, Guimarães FS. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology (Berlin) 2006;185:298-305.
19. Chrapko W, Jurasz P, Radomski MW, Archer SL, Newman SC, Baker G, et al. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology 2006;31: 1286-93. (Pubitemid 43971844)
20. Arslan A, Uzun M. Does the lower nitric oxide level cause cardiovascular changes in major depressed women? Eur Rev Med Pharmacol Sci 2008;12:309-13.
21. Ikenouchi-Sugita A, Yoshimura R, Hori H, Umene-Nakano W, Ueda N, Nakamura J. Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1451-3.
22. Kim YK, Paik JW, Lee SW, Yoon D, Han C, Lee BH. Increased plasma nitric oxide level associated with suicide attempt in depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1091-6. (Pubitemid 44202364)
23. Herken H, Akyol O, Yilmaz HR, Tutkun H, Savas HA, Ozen ME, et al. Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment. Hum Psychopharma-col 2005;21:53-9. (Pubitemid 43192476)
24. Kaya B, Unal S, Karabulut AB, Türköz Y. Altered diurnal variation of nitric oxide production in patients with panic disorder. Tohoku J Exp Med 2004;204:147-54. (Pubitemid 39335053)
25. Sánchez-Fernández C, González C, Mercer LD, Beart PM, Ruiz-Gayo M, Fernández-Alfonso MS. Cholecystokinin induces cerebral vasodilatation via presynaptic CCK2 receptors: new implications for the pathophysiology of panic. J Cereb Blood Flow Metab 2003;23:364-70. (Pubitemid 36307580)
26. Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res 1996;33:181-94. (Pubitemid 26164469)
27. Fantidis P. The role of the stress-related anti-inflammatory hormones ACTH and cortisol in atherosclerosis. Curr Vasc Pharmacol 2010;8:517-25.
28. Stanger O, Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med 2003;41:1444-54. (Pubitemid 37493559)
29. Wallerath T, Witte K, Schäfer SC, Schwarz PM, Prellwitz W, Wohlfart P, et al. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocor-ticoid-mediated hypertension. Proc Natl Acad Sci USA 1999;96;13357-62.
30. Rogers KM, Bonar CA, Estrella JL, Yang S. Inhibitory effect of glucocorticoid on coronary artery endothelial function. Am J Physiol Heart Circ Physiol 2002;283:1922-8.
31. Markovitz JH, Matthews KA. Platelets and coronary heart disease: potential psychophysiologic mechanisms. Psycho-som Med 1991;53:643-68.
32. von Känel R. Platelet hyperactivity in clinical depression and the beneficial effect of antidepressant drug treatment: how strong is the evidence? Acta Psychiatr Scand 2004;110: 163-77.
33. Parakh K, Sakhuja A, Bhat U, Ziegelstein RC. Platelet function in patients with depression. South Med J 2008;101:612-27.
34. Ataoglu A, Canan F. Mean platelet volume in patients with major depression: effect of escitalopram treatment. J Clin Psychopharmacol 2009;29:368-71.
35. Chen CS, Chou MC, Yeh YC, Yang YH, Lai CL, Yen CF, et al. Plasma homocysteine levels and major depressive disorders in Alzheimer disease. Am J Geriatr Psychiatry 2010;18:1045-8.
36. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry 2003;60:618-26. (Pubitemid 36682319)
37. Dittmann S, Seemüller F, Grunze HC. The impact of homo-cysteine levels on cognition in euthymic bipolar patients: a cross-sectional study. J Clin Psychiatry 2008;69:899-906. (Pubitemid 351944941)
38. Chellappa P, Ramaraj R. Depression, homocysteine concentration, and cardiovascular events. J Am Med Assoc 2009;301:1541-2.
39. Meier C, Harbrecht U, Liedtke R, Oldenburg J, Conrad R, Imbierowicz K, et al. Relative hyperhomocysteinemia in patients with panic disorder: a case-control study. Neuropsy-chobiology 2010;62:164-70.
40. Ravari H, Zafarghandi MR, Alvandfar D, Saadat S. Serum homocysteine in deep venous thrombosis, peripheral atherosclerosis and healthy Iranians: a case-control study. Pak J Biol Sci 2009;12:1019-24.
41. Pasterkamp G, Algra A, Grobbee DE, de Jaegere PP, Banga JD, van der Graaf Y. Homocysteine and the stage of atherosclerotic disease: a study in patients suffering from clinically silent and clinically manifest atherosclerotic disease. Eur J Clin Invest 2002;32:309-15. (Pubitemid 36228389)
42. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation 2001;103:2717-23. (Pubitemid 32538788)
43. Medici V, Peerson JM, Stabler SP, et al. Impaired homo-cysteine transsulfuration is an indicator of alcoholic liver disease. J Hepatol 2010;53:551-7.
44. Unt E, Zilmer K, Mägi A. Homocysteine status in former top-level male athletes: possible effect of physical activity and physical fitness. Scand J Med Sci Sports 2008;18:360-6.
45. Nascimento CM, Stella F, Garlipp CR. Serum homocysteine and physical exercise in patients with Parkinson's disease. Psychogeriatrics 2011;11:105-12.